Wegovy and Heart Disease: A Weight Loss Drug with Potential Heart-Saving Benefits
When semaglutide (brand name Wegovy) was approved for chronic weight management in 2021, it represented a major advance in obesity medicine. But the landmark SELECT trial, published in 2023, elevated semaglutide's significance even further—demonstrating that it reduces the risk of serious cardiovascular events in people with overweight or obesity, regardless of whether they have diabetes. This finding has profound implications for how clinicians approach both weight management and cardiovascular risk reduction.
The SELECT Trial: What It Found
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a randomized, double-blind, placebo-controlled trial involving 17,604 participants across 41 countries. All participants had pre-existing cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), a BMI of 27 or greater, and no history of type 2 diabetes—a critical distinction from earlier cardiovascular outcome trials with GLP-1 agonists.
Participants were randomized to receive weekly subcutaneous semaglutide (2.4 mg) or placebo and followed for a mean of 34 months. The primary endpoint was a composite of major adverse cardiovascular events (MACE): cardiovascular death, nonfatal myocardial infarction (heart attack), and nonfatal stroke.
The results were striking: semaglutide reduced the risk of MACE by 20% compared to placebo (6.5% vs. 8.0% event rate; hazard ratio 0.80, 95% CI 0.72–0.90; p less than 0.001). This reduction was statistically significant and clinically meaningful. The number needed to treat to prevent one cardiovascular event over approximately three years was approximately 67—comparable to the cardiovascular benefit of statins in high-risk populations.
Key Findings Beyond the Headline Number
Several secondary findings from SELECT are particularly noteworthy:
Heart failure hospitalization: Semaglutide reduced the rate of heart failure hospitalizations and urgent visits by 41%—one of the largest treatment effects ever observed for heart failure outcomes with a pharmacological intervention in this population.
All-cause mortality trend: While not statistically significant on its own, there was a favorable trend toward reduced all-cause mortality in the semaglutide group.
Kidney outcomes: Semaglutide reduced the composite kidney disease outcome (worsening of kidney function, dialysis, kidney transplant, or kidney-related death) by 22%, adding to a growing body of evidence for cardiorenal protection with GLP-1 therapy.
Consistent across subgroups: The cardiovascular benefit was consistent across age, sex, race, geographic region, baseline BMI, and degree of weight loss achieved—suggesting that the mechanism extends beyond weight loss itself.
The Mechanism: Beyond Weight Loss
The cardiovascular benefit in SELECT cannot be fully explained by weight loss alone, for several reasons. First, weight loss alone—even significant weight loss—has not consistently reduced MACE in prior cardiovascular outcome trials. Second, the benefit was consistent in patients who lost relatively little weight, suggesting a weight-loss-independent mechanism.
Current evidence points to several mechanisms by which semaglutide may reduce cardiovascular risk directly:
Anti-inflammatory effects: GLP-1 receptors are expressed on immune cells, endothelial cells, and cardiac myocytes. Semaglutide reduces CRP, IL-6, and other inflammatory markers—dampening the chronic inflammation that drives atherosclerosis progression.
Improved endothelial function: GLP-1 agonists improve nitric oxide availability in the vascular endothelium, reducing arterial stiffness and improving vasodilation.
Blood pressure reduction: Semaglutide consistently reduces systolic blood pressure by 4–6 mmHg, independently contributing to cardiovascular risk reduction.
Lipid effects: Semaglutide reduces triglycerides and favorably remodels LDL particle size, reducing the atherogenic potential of LDL cholesterol.
Direct cardiac effects: GLP-1 receptors in the heart may mediate direct cardioprotective effects, including improved myocardial energy metabolism and reduced myocardial oxidative stress.
Implications for Clinical Practice
SELECT fundamentally reframes semaglutide as a cardiovascular drug, not merely a weight loss drug. For patients with established cardiovascular disease and excess body weight, weekly semaglutide now has a level of evidence supporting its use that is comparable to other proven cardioprotective therapies like statins, ACE inhibitors, and beta-blockers.
Importantly, the SELECT findings do not make lifestyle intervention or hormonal optimization unnecessary. The cardiovascular benefit of semaglutide adds to—it does not replace—the benefits of optimized hormones, exercise, and nutrition. In fact, patients who lose more weight and achieve better metabolic control are likely to gain additional benefit beyond the cardiovascular effects shown in SELECT.
Is Semaglutide Right for You?
Semaglutide is a prescription medication that requires medical supervision. Not every patient is a candidate, and dosing, monitoring, and integration with other therapies should be managed by an experienced physician. When combined with BHRT and comprehensive metabolic care, it offers patients a powerful and evidence-based strategy for both weight management and cardiovascular protection.
Dr. Kenton Bruice, MD, provides medically supervised GLP-1 therapy alongside comprehensive BHRT and metabolic care at his clinics in Denver, Aspen, and St. Louis. If you are concerned about your cardiovascular risk and weight, schedule a consultation with Dr. Bruice to explore your options.